Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.
Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...
A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.
Nuvectis Pharma’s NXP800 shows potential in ovarian cancer but is early stage. Find out why NVCT stock is best suited for ...
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...
Experts say ovarian cancer causes more deaths than all other female reproduction system cancers and is difficult to diagnose ...
The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
Bevacizumab, known commercially as Avastin, is a drug your oncologist may suggest during the treatment process for ovarian cancer. The drug works by preventing blood flow to tumors, which can stop a ...